ATRC
HoldPremium GrowerFLAGAtriCure, Inc. · Healthcare · United States · $2.5B · Avg Vol: $67M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
Insufficient evidence for a screen-pass. AtriCure, Inc.: fails the quant gate on value (Q65/V18/M75; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT ATRICURE, INC.
Read
AtriCure, Inc. is a medical device company dedicated to developing, manufacturing, and selling products for the treatment of atrial fibrillation (Afib) and other cardiac arrhythmias. The company is a recognized market leader in surgical Afib solutions, offering a comprehensive portfolio of ablation systems and cryoablation products. AtriCure's competitive advantage stems from its strong intellectual property, extensive clinical evidence, and established surgeon relationships in this specialized field.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 330.4M | 399.2M | 465.3M | 534.5M | 17.4% | 569.6M | 606.2M | 679.7M | 12.8% |
| EPS | -1.02 | -0.66 | -0.95 | -0.24 | — | 0.21 | 0.28 | 0.43 | — |
| Shares | 46.6M | 47.5M | 48.9M | 49.8M | +6.9% | 50.9M | — | — | — |
| Debt | 74.5M | 74.5M | 73.7M | 73.4M | -0.5% | 74.2M | — | — | — |
| Equity | 456.8M | 466.2M | 461.0M | 491.9M | 2.5% | — | — | — | — |
| Op CF | -22.1M | 4.5M | 12.2M | 57.3M | 257.6% | 64.9M | — | — | — |
| Inv CF | 44.0M | 21.8M | 30.2M | -14.6M | — | — | — | — | — |
| Fin CF | -7.1M | -32.0K | -3.6M | 1.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATRC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATRC | AtriCure, Inc.(you) | $2.5B | 64 | Hold |
| XRAY | DENTSPLY SIRONA Inc. | $2.2B | 58 | Hold |
| ICUI | ICU Medical, Inc. | $4.4B | 63 | Hold |
| LMAT | LeMaitre Vascular, Inc. | $1.8B | 53 | Hold |
| TFX | Teleflex Incorporated | $5.9B | 66 | Buy |
| BLFS | BioLife Solutions, Inc. | $1.8B | 50 | Hold |
| STAA | STAAR Surgical Company | $1.1B | 57 | Hold |
| AZTA | Azenta, Inc. | $1.4B | 46 | Hold |
| NVST | Envista Holdings Corporation | $4.4B | 85 | Strong Buy |
| AVTR | Avantor, Inc. | $9.9B | 70 | Buy |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.